In Sellas Life Sciences’ Leukemia Trial, 80 Events Will Settle a $2.3 Billion Bet

Sellas stock surges 631% but trades 19% below record high as phase 3 REGAL trial awaits two final deaths. Analysts split on delay meaning.

The numbers tell a story of extremes. Over the past twelve months, Sellas Life Sciences shares have surged by 631% — or as much as 660% by some calculations — propelling the company’s market capitalization to €2.33 billion. Yet the stock closed Thursday at €12.30, some 19% below its record high of €15.25 set on June 30, 2026, after a week that saw it dip as low as €11.85. The gap between those peaks and troughs reflects a market caught between euphoria and dread.

The source of that tension is a single clinical milestone: the REGAL Phase 3 trial testing Galinpepimut-S (GPS) as a maintenance therapy for patients with acute myeloid leukemia in second complete remission. The study requires exactly 80 deaths — referred to as “events” — before the data can be unblinded and analyzed. As of this week, the count stands at 78.

Two more fatalities. That is all that separates the company from a verdict that will either validate its €2.33 billion valuation or send it into a tailspin.

Optimists vs. Skeptics: The Waiting Game

The prolonged wait for those final events has become a battleground of interpretations. James Molloy of Alliance Global, who this week raised his price target on Sellas from $10 to $25 while maintaining a Buy rating, framed the delay as deeply encouraging. “The fact that the events are taking longer suggests treated patients are living longer than expected,” he argued — a potential sign of a blockbuster survival benefit.

On the other side, short sellers have speculated that the delay could stem from improvements in standard of care that are extending survival in the control arm as well, muddying the trial’s signal. Sellas CEO Angelos Stergiou pushed back sharply, noting that no approved maintenance therapy exists for second complete remission, making such comparisons irrelevant. He also stressed that the market was undervaluing the rest of the company’s pipeline.

The RSI of 66.3 and a 30-day annualized volatility of 125.45% illustrate just how charged the atmosphere has become. The stock trades 60% above its 50-day moving average of €7.67 and more than 212% above its 200-day average of €3.94 — distances that typically signal a market pricing in a binary outcome well before the data arrives.

The Analyst Consensus and the Second Arrow

Despite the uncertainty, the analyst community remains broadly optimistic. The consensus price target stands at €15.30, implying about 24% upside from current levels. Yet that relatively modest target sits in sharp contrast to Molloy’s $25 projection, highlighting the wide divergence in expectations.

Away from the REGAL spotlight, Sellas is quietly building a second pillar. SLS009, an oral CDK9 inhibitor, is advancing through Phase 2 development. For the retail investors who have fueled much of the recent rally, however, that earlier-stage program remains a footnote — at least until the main event is resolved.

The Shadow of Dilution and the Road Ahead

Even as the stock rides high, a persistent risk looms: Sellas maintains an at-the-market financing program that allows it to issue up to $150 million in new shares at any time. With cash burn remaining a concern, dilution is a constant fear that has already contributed to recent selling pressure.

Speculation about a potential takeover or strategic partnership has also surfaced, fueled by contractual change-of-control clauses and a small disclosed position by CoreCap Advisors. Analysts caution that such moves remain unsubstantiated, but they add another layer of narrative heat to an already overheated stock.

For now, the focus is locked on the REGAL count. Once the 80th event is recorded, Sellas will unblind the survival data. If the result is positive, the stock’s spectacular run will find fundamental support. If not, the premium built over the past 12 months will evaporate as quickly as it appeared. The final two events will decide which path the company takes.